Investigating how ion channels and membrane receptors affect pulmonary arterial hypertension
Official title: Ion Channels and Membrane Receptors in Pulmonary Arterial Hypertension
Funded at University of Florida · NIH-11228445 · Data updated 2026-11-12
This study is looking into how certain proteins and channels in the blood vessels of the lungs might cause problems for people with pulmonary arterial hypertension (PAH), with the goal of finding new ways to help improve their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $1,352,400 |
| NIH project number | 7R35HL171538-02 |
| Project ID | NIH-11228445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those experiencing severe symptoms.
✕Less likely to help
Patients with other forms of pulmonary hypertension or those without a diagnosis of pulmonary arterial hypertension may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. It explores how certain ion channels and receptors in the cells of the pulmonary arteries contribute to the disease's progression by affecting cell contraction and growth. The study involves examining the role of specific proteins and signaling pathways that may lead to vascular remodeling and increased resistance in the pulmonary vasculature. By using animal models, the research aims to identify potential therapeutic targets that could improve outcomes for patients with PAH.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life and survival rates for patients with pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in targeting ion channels and receptors for treating similar vascular conditions, indicating potential for success in this approach.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Yuan, Jason X J — University of Florida
- Study coordinator: Yuan, Jason X J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.